The search for new triazole antifungal agents.
The first generation antifungal agent triazoles, fluconazole and itraconazole, have revolutionised the treatment of serious fungal infections such as mucosal and invasive candidiasis and cryptococcal meningitis. However, the treatment of some fungal infections, particularly aspergillosis, is still far from satisfactory and thus there is an important requirement for new broad-spectrum antifungal agents. The new second generation triazoles voriconazole and SCH-56592 show considerable promise in achieving this goal in the near future.
Millennium Pharmaceuticals Inc, Division of Molecular and Cellular Biology, 640 Memorial Drive, Cambridge, MA 02139, USA. koltin@mpi.com
Y
Y
Koltin
C A
CA
Hitchcock
D000935:Antifungal Agents / Q000737:chemistry / Q000494:pharmacology*; D015507:Drugs, Investigational / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D011743:Pyrimidines / Q000494:pharmacology; D014230:Triazoles / Q000737:chemistry / Q000494:pharmacology*; D065819:Voriconazole
D000935:Antifungal Agents; D015507:Drugs, Investigational; D011743:Pyrimidines; D014230:Triazoles; C058219:ICI 195739; C101425:posaconazole; D065819:Voriconazole